HRP20090018T3 - Novel heterocyclic oxime derivatives, method for preparing same and use thereof as hypoglycaemic or hypolipidemic agents - Google Patents
Novel heterocyclic oxime derivatives, method for preparing same and use thereof as hypoglycaemic or hypolipidemic agentsInfo
- Publication number
- HRP20090018T3 HRP20090018T3 HR20090018T HRP20090018T HRP20090018T3 HR P20090018 T3 HRP20090018 T3 HR P20090018T3 HR 20090018 T HR20090018 T HR 20090018T HR P20090018 T HRP20090018 T HR P20090018T HR P20090018 T3 HRP20090018 T3 HR P20090018T3
- Authority
- HR
- Croatia
- Prior art keywords
- straight
- branched
- group
- same
- different
- Prior art date
Links
- 239000003524 antilipemic agent Substances 0.000 title 1
- -1 heterocyclic oxime Chemical class 0.000 title 1
- 230000002218 hypoglycaemic effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 239000001301 oxygen Substances 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000005018 aryl alkenyl group Chemical group 0.000 abstract 2
- 125000005015 aryl alkynyl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000004447 heteroarylalkenyl group Chemical group 0.000 abstract 2
- 125000005312 heteroarylalkynyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 239000011593 sulfur Chemical group 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 150000003536 tetrazoles Chemical class 0.000 abstract 2
- 150000001336 alkenes Chemical class 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004957 naphthylene group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Chemical group 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 125000006684 polyhaloalkyl group Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0500841A FR2881138B1 (fr) | 2005-01-27 | 2005-01-27 | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| PCT/FR2006/000175 WO2006079720A1 (fr) | 2005-01-27 | 2006-01-26 | Nouveaux derives d1oximes heterocycliques, leur procede de preparation et leur utilisation comme agents hypoglycemiants et hypoli pemiants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090018T3 true HRP20090018T3 (en) | 2009-02-28 |
Family
ID=34954345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090018T HRP20090018T3 (en) | 2005-01-27 | 2009-01-14 | Novel heterocyclic oxime derivatives, method for preparing same and use thereof as hypoglycaemic or hypolipidemic agents |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20080113974A1 (xx) |
| EP (1) | EP1844029B1 (xx) |
| JP (1) | JP2008528561A (xx) |
| KR (1) | KR20070097108A (xx) |
| CN (1) | CN101133040A (xx) |
| AR (1) | AR052663A1 (xx) |
| AT (1) | ATE414066T1 (xx) |
| AU (1) | AU2006208811A1 (xx) |
| BR (1) | BRPI0607085A2 (xx) |
| CA (1) | CA2595975A1 (xx) |
| DE (1) | DE602006003630D1 (xx) |
| DK (1) | DK1844029T3 (xx) |
| EA (1) | EA012437B1 (xx) |
| ES (1) | ES2318727T3 (xx) |
| FR (1) | FR2881138B1 (xx) |
| HR (1) | HRP20090018T3 (xx) |
| MA (1) | MA29258B1 (xx) |
| MX (1) | MX2007009072A (xx) |
| NO (1) | NO20074346L (xx) |
| PL (1) | PL1844029T3 (xx) |
| PT (1) | PT1844029E (xx) |
| SI (1) | SI1844029T1 (xx) |
| WO (1) | WO2006079720A1 (xx) |
| ZA (1) | ZA200706248B (xx) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101805754B1 (ko) | 2008-12-08 | 2017-12-07 | 먼디파머 인터내셔널 코포레이션 리미티드 | 단백질 수용체 티로신 키나아제 억제제의 조성물 |
| US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
| US10301271B2 (en) | 2014-09-17 | 2019-05-28 | Purdue Pharma L.P. | Crystalline forms of tyrosine kinase inhibitors and their salts |
| GB201508864D0 (en) * | 2015-05-22 | 2015-07-01 | Glaxosmithkline Ip Dev Ltd | Compounds |
| CN106478452B (zh) * | 2015-09-01 | 2018-08-21 | 上海医药工业研究院 | 吉非罗齐肟类衍生物及其作为fxr拮抗剂的应用 |
| CN106478453B (zh) * | 2015-09-01 | 2018-08-24 | 上海医药工业研究院 | 肟类衍生物及其作为fxr拮抗剂的应用 |
| CN112370455A (zh) * | 2020-10-19 | 2021-02-19 | 济南大学 | 一种磺酰胺衍生物作为α-葡萄糖苷酶抑制剂及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2853649B1 (fr) * | 2003-04-09 | 2006-07-14 | Servier Lab | Nouveaux derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2005
- 2005-01-27 FR FR0500841A patent/FR2881138B1/fr not_active Expired - Fee Related
-
2006
- 2006-01-26 CN CNA2006800064789A patent/CN101133040A/zh active Pending
- 2006-01-26 AR ARP060100287A patent/AR052663A1/es unknown
- 2006-01-26 DK DK06709172T patent/DK1844029T3/da active
- 2006-01-26 ES ES06709172T patent/ES2318727T3/es active Active
- 2006-01-26 SI SI200630149T patent/SI1844029T1/sl unknown
- 2006-01-26 AT AT06709172T patent/ATE414066T1/de not_active IP Right Cessation
- 2006-01-26 EA EA200701476A patent/EA012437B1/ru not_active IP Right Cessation
- 2006-01-26 PT PT06709172T patent/PT1844029E/pt unknown
- 2006-01-26 EP EP06709172A patent/EP1844029B1/fr active Active
- 2006-01-26 AU AU2006208811A patent/AU2006208811A1/en not_active Abandoned
- 2006-01-26 JP JP2007552680A patent/JP2008528561A/ja active Pending
- 2006-01-26 ZA ZA200706248A patent/ZA200706248B/xx unknown
- 2006-01-26 CA CA002595975A patent/CA2595975A1/fr not_active Abandoned
- 2006-01-26 BR BRPI0607085-0A patent/BRPI0607085A2/pt not_active IP Right Cessation
- 2006-01-26 MX MX2007009072A patent/MX2007009072A/es active IP Right Grant
- 2006-01-26 US US11/883,121 patent/US20080113974A1/en not_active Abandoned
- 2006-01-26 DE DE602006003630T patent/DE602006003630D1/de not_active Expired - Fee Related
- 2006-01-26 KR KR1020077018499A patent/KR20070097108A/ko active IP Right Grant
- 2006-01-26 WO PCT/FR2006/000175 patent/WO2006079720A1/fr active Application Filing
- 2006-01-26 PL PL06709172T patent/PL1844029T3/pl unknown
-
2007
- 2007-08-17 MA MA30149A patent/MA29258B1/fr unknown
- 2007-08-27 NO NO20074346A patent/NO20074346L/no not_active Application Discontinuation
-
2009
- 2009-01-14 HR HR20090018T patent/HRP20090018T3/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070097108A (ko) | 2007-10-02 |
| BRPI0607085A2 (pt) | 2009-08-04 |
| AU2006208811A1 (en) | 2006-08-03 |
| EA200701476A1 (ru) | 2008-02-28 |
| ES2318727T3 (es) | 2009-05-01 |
| FR2881138B1 (fr) | 2007-03-02 |
| DE602006003630D1 (de) | 2008-12-24 |
| NO20074346L (no) | 2007-08-27 |
| PL1844029T3 (pl) | 2009-04-30 |
| WO2006079720A8 (fr) | 2007-10-25 |
| ZA200706248B (en) | 2009-06-24 |
| MX2007009072A (es) | 2007-10-04 |
| CA2595975A1 (fr) | 2006-08-03 |
| PT1844029E (pt) | 2008-12-19 |
| SI1844029T1 (sl) | 2009-02-28 |
| JP2008528561A (ja) | 2008-07-31 |
| DK1844029T3 (da) | 2009-03-02 |
| EP1844029B1 (fr) | 2008-11-12 |
| AR052663A1 (es) | 2007-03-28 |
| MA29258B1 (fr) | 2008-02-01 |
| EA012437B1 (ru) | 2009-10-30 |
| WO2006079720A1 (fr) | 2006-08-03 |
| ATE414066T1 (de) | 2008-11-15 |
| FR2881138A1 (fr) | 2006-07-28 |
| US20080113974A1 (en) | 2008-05-15 |
| EP1844029A1 (fr) | 2007-10-17 |
| CN101133040A (zh) | 2008-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090018T3 (en) | Novel heterocyclic oxime derivatives, method for preparing same and use thereof as hypoglycaemic or hypolipidemic agents | |
| TW200633991A (en) | Chemical compounds | |
| HRP20070117T3 (en) | Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type ii diabetes | |
| MY153045A (en) | Oxopyrazine derivative and herbicide | |
| CO6241101A2 (es) | Derivados de quinolina como inhibidores de la p13 quinasa | |
| AR057023A1 (es) | Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa | |
| CO5180568A1 (es) | Compuestos farmaceuticos, especialmente mutilinas, composiciones farmaceuticas que los contienen | |
| PE20130375A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
| NO20073667L (no) | [4-(heteroaryl) piperazin-1-yl]-(2,5-substituert-fenyl)metanonderivater som glycintransportor 1(GLYT-1)- inhibitorer for behandling av neurologiske og neuropsykiatriske lidelser | |
| RS54638B1 (en) | HCV SERIN PROTEASE INHIBITORS DERIVED FROM MACROCYCLIC PROLINE | |
| EP2594555A4 (en) | HETEROCYCLIC COMPOUND, AND P27 KIP1 DEGRADATION INHIBITOR | |
| TR200401413T1 (tr) | Dibenzilamin bileşikleri ve bunların farmasötik kullanımları | |
| AR048669A1 (es) | Derivados biciclicos de bisamida | |
| NO20065494L (no) | Fuserte kinolinderivater og anvendelse derav | |
| AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| UY31014A1 (es) | Derivados de ftalazinona | |
| AR074608A1 (es) | Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas | |
| MX2010008361A (es) | Derivados de arilamida oxazepinopirimidona sustituidos. | |
| ATE546467T1 (de) | Ortho-nitrosophenole als polymerisationshemmer | |
| MX2009012380A (es) | Compuestos de heteroarilamida pirimidona. | |
| SE0201937D0 (sv) | Therapeutic agents | |
| EA200971060A1 (ru) | Гетероариламидные пиримидоновые производные | |
| ATE433440T1 (de) | Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren | |
| EA200501526A1 (ru) | Производные 4-замещённых хинолинов, способ и промежуточные продукты для их получения и содержащие их фармацевтические композиции | |
| DE502006008710D1 (de) | Substituierte tetrahydroisochinoline als mmp-inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament |